SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    Sanity Group closes Europe’s largest cannabis investment round

    By
    Home / Sanity Group closes Europe’s largest cannabis investment round

    German cannabis company Sanity Group has announced the closing of its $37.6m Series B fundraising round led by British American Tobacco (BAT Group).

    The company has said that ongoing commitment from existing Sanity Group investors such as Redalpine and Snoop Dogg’s venture capital firm, Casa Verde Capital, brings the total funds raised to over $100m.

    BAT, via one of its wholly owned group companies, has now acquired a non-controlling minority stake in the company.

    The new investment will fuel Sanity Group’s growth and enable its expansion across Europe, as well as strengthen its research and development activities.

    Read more: Snoop Dogg venture capital firm invests in savoury cannabis edibles

    Founder and CEO of Sanity Group, Finn Age Hänsel, commented: “This funding is an important milestone for us and a strong signal towards the future of cannabis in Germany and Europe. I am grateful for the belief shown by both new and existing investors. 

    “Our goal is to leverage the full potential of the cannabis plant and to explore and harness the different cannabinoids – with the new capital, we will be able to accelerate our medical and consumer business units whilst preparing accordingly for cannabis legalisation in Germany.”

    “This financing round is not only the largest funding round achieved by a European cannabis company to date, but also one of the few upsizing rounds in this current economic phase of the German startup scene,” added Max Narr, chief investment officer of Sanity Group.

    “Against the backdrop of a challenging global economy, we are proud to have achieved a funding round of this magnitude, facilitating the pursuit and progress of our mission to become a significant cannabis brand in Germany and Europe.”

    BAT’s investment adds a European dimension to its exploration of work beyond nicotine, says the company, and is complementary to other recent investments made by BAT or BAT companies. In particular, its R&D collaboration established with Canada’s Organigram Holdings Inc. announced in March last year.

    Chief growth officer at BAT, Kingsley Wheaton, said: “Investing in Sanity Group is another example of BAT’s ongoing work to explore numerous areas beyond nicotine, positioning BAT for future portfolio growth across a range of categories and geographies.

    “We continue to transform our business, through better understanding of our current and future consumers, as part of our A Better Tomorrow purpose.”

    “Our mission is to help aspiring companies become tomorrow’s market leaders. We invest in curious minds with a shared passion to innovate. We have felt this passion from the Sanity Group team since our involvement in the summer of 2021, and we look forward to accompanying their further development in the future”, said Michael Sidler, Partner at Swiss VC Redalpine, lead investor in the Series A financing round in 2021.

    Karan Wadhera, managing partner at Casa Verde Capital, added: “Sanity Group is already the most well capitalised cannabis business in Germany and is on track to become one of the leading brands in Europe. We are thrilled with their continued progress and will keep offering financial and operational support as they scale.”

    Alongside Swiss VC Redalpine and Casa Verde Capital, Sanity Group’s existing investors also include music producer Will.I.Am of the Black Eyed Peas, Hollywood actress Alyssa Milano, manager Scooter Braun, HV Capital, Calyx, TQ Ventures, Atlantic Food Labs, Cherry Ventures, Bitburger Ventures, SevenVentures, GMPVC, Navy Capital and SOJE Capital.

    [activecampaign form=31]

    10 June 2026 · Berlin Sales end May 29

    European Cannabis
    Insights Summit

    From €216

    200+ industry leaders. Exclusive German market data. A half-day briefing for B2B operators in Europe's most important emerging cannabis market.

    Stephanie Price

    Stephanie is a journalist for Business of Cannabis, writing about science, research, policy and industry developments in cannabis, CBD and psychedelics. In 2013 Stephanie gained her BA in English and Media, focusing on journalism and propaganda, where her magazine ‘Game Theory’ focused on developments and disruptors over the coming decade including cannabis, psychedelics, blockchain/crypto and free speech. In 2015 Stephanie received her National Council for the Training of Journalists (NCTJ) diploma whilst working as a reporter in North Wales. Stephanie has a specialism in Medical Cannabis: The Health Effects of THC and CBD through the University of Colorado, and a certificate from the Medical Cannabis Clinicians Society on “Medical Cannabis Explained”.

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free